Sanofi Builds OTC Business Through Organic Growth And Bolt-Ons
This article was originally published in The Tan Sheet
Sanofi-Aventis in its latest quarter made headway toward doubling its OTC business by 2014, reporting 7.4 percent organic growth and 26.3 percent growth including acquisitions in the segment
You may also be interested in...
A joint venture with Minsheng Pharmaceutical Group brings Sanofi-Aventis one step closer to its goal of doubling its consumer health care business in five years and opens a powerful distribution channel in China through which the French firm can market newly acquired supplements
Sanofi-Aventis' $1.9 billion bid for OTC and personal care product firm Chattem offers the French firm a coveted toehold in the sizeable U.S. consumer health care market while also opening potential opportunities in emerging markets
The deal, which is Sanofi's latest attempt to diversity in the face of a looming patent cliff, provides a platform for Rx-to-OTC switches.